← Leaderboards
Raymond L Konger
University Of Rochester
$2,583,958
Attributed
$3,533,460
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $625.9K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,533,460 · 5
VA$0 · 2
By mechanism
R01$1,899,005 · 1
R21$867,225 · 2
K08$617,490 · 1
R03$149,740 · 1
I01$0 · 2
Top collaborators
- Jeffrey B. Travers5 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Patricia Janet Sime$8,180,472
Others in their field
Top investigators on “Production”
- Eric S Lander · Whitehead Institute For Biomedical Res$568,626,051
- Bambra Strokes · Ppd Development Lp$526,656,217
- Richard A Gibbs · Baylor College Of Medicine$521,766,399
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- David Heimbrook · Leidos Biomedical Research, Inc.$332,994,970
Research focus
ProductionMediatingMalignant NeoplasmsCutaneousIn VivoUltraviolet RaysOxidative StressResponseAreaPpar GammaSkin CancerAgonistPlayKeratinocyteInsightTumorLeadDesignSignal TransductionInflammatoryBaseSkinEpidermisChemopreventive Agent
Grant awards (26)
Promotion of photocarcinogenesis by the senescent field and mechanisms for field persistence$0
I01 · FY2025 · VA · contact PI
Promotion of photocarcinogenesis by the senescent field and mechanisms for field persistence$0
I01 · FY2024 · VA · contact PI
Promotion of photocarcinogenesis by the senescent field and mechanisms for field persistence$0
I01 · FY2023 · VA · contact PI
Promotion of photocarcinogenesis by the senescent field and mechanisms for field persistence$0
I01 · FY2022 · VA · contact PI
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling$0
I01 · FY2021 · VA · contact PI
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling$0
I01 · FY2020 · VA · contact PI
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling$0
I01 · FY2019 · VA · contact PI
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling$0
I01 · FY2018 · VA · contact PI
Regulation of cutaneous immune function and anti-tumor immune responses by PPARgamma-mediated transrepressive signaling$0
I01 · FY2017 · VA · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$362,855
R01 · FY2013 · HL
Characterization of persistent hyperemic foci and their role in photocarcinogenes$187,575
R21 · FY2013 · ES · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$381,150
R01 · FY2012 · HL
Characterization of persistent hyperemic foci and their role in photocarcinogenes$244,720
R21 · FY2012 · ES · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$385,000
R01 · FY2011 · HL
Platelet Activating Factor and Epidermal Cytotoxicity$385,000
R01 · FY2010 · HL
Tumor Suppression Through Oxidized Glycerophosphocholines$192,500
R21 · FY2010 · ES · contact PI
Tumor Suppression Through Oxidized Glycerophosphocholines$11,430
R21 · FY2010 · ES · contact PI
Platelet Activating Factor and Epidermal Cytotoxicity$385,000
R01 · FY2009 · HL
Tumor Suppression Through Oxidized Glycerophosphocholines$231,000
R21 · FY2009 · ES · contact PI
Role of PPARgamma in ultraviolet stress responses$73,990
R03 · FY2008 · AR · contact PI
Role of PPARgamma in ultraviolet stress responses$75,750
R03 · FY2007 · AR · contact PI
ROLE OF PGE2 RECEPTORS EP2 AND EP3 ON SENESCENCE$123,498
K08 · FY2004 · AR
ROLE OF PGE2 RECEPTORS EP2 AND EP3 ON SENESCENCE$123,498
K08 · FY2003 · AR
ROLE OF PGE2 RECEPTORS EP2 AND EP3 ON SENESCENCE$123,498
K08 · FY2002 · AR
ROLE OF PGE2 RECEPTORS EP2 AND EP3 ON SENESCENCE$123,498
K08 · FY2001 · AR
ROLE OF PGE2 RECEPTORS EP2 AND EP3 ON SENESCENCE$123,498
K08 · FY2000 · AR